Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pasithea Therapeutics Corp. - Common Stock (NQ:KTTA)

1.270 UNCHANGED
Streaming Delayed Price Updated: 3:51 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pasithea Therapeutics Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
Via InvestorPlace
Lucy Scientific Goes After Pasithea Therapeutics Common Shares For A '142% Premium' Deal
Health Canada-licensed psychedelics producer Lucy Scientific Discovery (NASDAQ: LSDI) announced it has sent a proposal to biotech business Pasithea Therapeutics Corp. 
Via Benzinga
Disney, Amgen, First Republic, Psychedelics: How One CEO's Universal Deal-Making Approach Shapes Industries
In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I've been... maybe you could conclude that they... 
Via Benzinga
Why Pasithea Therapeutics Stock Is Up Today
Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares are up Monday after Lucy Scientific Discovery (NASDAQ: LSDI) proposed to acquire the company. 
Via Benzinga
Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive
Via Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Learn More about Pasithea Therapeutics by gaining access to the latest research report 
Via TheNewswire.com
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
Via Business Wire
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
From CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
Via Business Wire
A New BioTech Research Race Is Focused On Improving Life For MS Patients
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is... 
Via Benzinga
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired AlloMek Therapeutics LLC, a privately-held biotechnology company,  
Via Benzinga
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
Exposures COVID-19
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.    
Via Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
By Mark Gilman, Benzinga 
Via News Direct
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease. 
Via Benzinga
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
Via Get News
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
From Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via Business Wire
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
From Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
From CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
Via Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.